Dysentery, Bacillary: all 61 studies
Page 1 of 1. Open to participants first (6), then studies with results posted, then the rest; newest registration first within each.
- Safety and Immunogenicity Study of IP-QSV Vaccine in Healthy Adults/Adolescents, Children and InfantsNot yet recruitingNCT07666750Phase 1/2
- The Impact of Shigellosis and Recommended Treatment in ChildrenRecruitingNCT07433426Phase 2
- First in Human Dose Escalation Study Evaluating the Safety and Immunogenicity of IVT's Shigella-04 Vaccine in Healthy Young AdultsRecruitingNCT07205926Phase 1
- Safety, and Efficacy Study of ShigETEC, a Live, Attenuated, Oral Combination Vaccine to Prevent Shigella and ETEC Disease Delivered to Healthy Adults Ages 18 to 50 Years OldRecruitingNCT07049159Phase 2
- InvaplexAR-Detox and DmLT Adjuvant in the Netherlands and ZambiaRecruitingNCT05961059Phase 1
- Shigella Sonnei 53G Human Infection Study in Kenyan AdultsRecruitingNCT05959616Phase 1
- A Study on the Immune Response and Safety of a Multicomponent Shigella Vaccine in Preventing Shigellosis in InfantsCompletedNCT06663436Phase 2Results posted
- A Study on the Safety and Immune Responses to the GVGH altSonflex1-2-3 Vaccine Against Shigellosis in Adults, Children, and InfantsCompletedNCT05073003Phase 1/2Results posted
- Controlled Human Infection Model Challenge/RechallengeCompletedNCT04992520Phase 1Results posted
- Shigella CVD 31000: Study of Responses With Shigella-ETEC Vaccine Strain CVD 1208S-122CompletedNCT04634513Phase 1Results posted
- Phase 2 Shigella Vaccine and ChallengeCompletedNCT04242264Phase 2Results posted
- Shigella CVD 30000: Study of Responses to Vaccination With Shigella VaccineCompletedNCT04078022Phase 2Results posted
- Dose Escalating Study of Intramuscular Invaplex[AR-DETOX]CompletedNCT03869333Phase 1Results posted
- A Study to Evaluate the Efficacy, Safety and Immunogenicity of a Vaccine Designed to Protect Against Infection With Shigella Sonnei in Healthy AdultsCompletedNCT03527173Phase 2Results posted
- A Study to Evaluate Safety and Immunogenicity of 1 Booster Dose of 1790GAHB Vaccine in Healthy Adults Primed With 3 Doses of 1790GAHB Vaccine in Study H03_01TP Compared to 1 Vaccination of 1790GAHB in Either Subjects Who Received Placebo in the Same Study or naïve Subjects Not Part of H03_01TP StudyCompletedNCT03089879Phase 1Results posted
- Shigella WRSS1 Vaccine Trial in BangladeshCompletedNCT02934178Phase 1Results posted
- Dose-Finding Study of Lyophilized Shigella Sonnei 53G Challenge StrainCompletedNCT02816346Phase 1Results posted
- Phase 2b Challenge Study With the Bioconjugate Vaccine Flexyn2aCompletedNCT02646371Phase 2Results posted
- Safety and Immunogenicity of Artificial Invaplex (Shigella Flexneri 2a InvaplexAR)CompletedNCT02445963Phase 1Results posted
- A Phase 1, Dose Escalation Study, to Evaluate a New Shigella Sonnei Vaccine in Healthy Adults.CompletedNCT02017899Phase 1Results posted
- Safety Study of Live Attenuated Oral Shigella (WRSS1) Vaccine in Bangladeshi Adults and ChildrenCompletedNCT01813071Not applicableResults posted
- Safety Study of Inactivated Shigella Whole Cell Vaccine in AdultsCompletedNCT01509846Phase 1Results posted
- Safety and Efficacy Study of WRSS1, a Shigella Sonnei Vaccine CandidateCompletedNCT01080716Phase 1/2Results posted
- Rifaximin for Prevention of Travellers' DiarrheaCompletedNCT00742469Phase 3Results posted
- Shigella Flexneri 2a Invaplex 50 Vaccine Dose Finding and Assessment of ProtectionCompletedNCT00485134Phase 1/2Results posted
- Safety, Immunogenicity and Efficacy of Shigella Conjugate Vaccines in 1-4 Year Olds in IsraelCompletedNCT00368316Phase 3Results posted
- Clinical Trial of the S. Flexneri-S. Sonnei Bivalent Conjugate VaccineActive, not recruitingNCT06838195Phase 3
- A Human Challenge Study to Assess Protection of a Shigella Tetravalent Bioconjugate VaccineCompletedNCT06615375Phase 2
- Study to Expand Safety and Immunogenicity Data With Shigella Bioconjugate Vaccine (Shigella4V2) in 9-month-old Infants.CompletedNCT06523231Phase 2
- Enterics for Global Health (EFGH)Active, not recruitingNCT06047821
- ShigETEC Vaccine Study in BangladeshCompletedNCT05987488Phase 1
- Phase 1 Trial for Safety, Tolerability, and Immunogenicity of a Live, Attenuated, Oral Shigella/ETEC Combination Vaccine to Healthy AdultsCompletedNCT05409196Phase 1
- Safety and Efficacy of the Bacteriophage Preparation, ShigActive™, in a Human Experimental Model of ShigellosisActive, not recruitingNCT05182749Phase 1/2
- Efficacy, Immunogenicity and Safety of S. Flexneriza-S. Sonnei Bivalent Conjugate Vaccine in Volunteers Aged From 6 Months to 5 YearsStatus unknownNCT05156528Phase 3
- Tebipenem Trial in Children With ShigellosisCompletedNCT05121974Phase 2
- Immunogenicity and Safety of S.Flexneriza-S.Sonnei Bivalent Conjugate Vaccine in Volunteers Aged From 3 Months to 5 Years OldCompletedNCT04865497Phase 2
- Egg Intervention During Pregnancy in IndonesiaActive, not recruitingNCT04694235Not applicable
- A Study to Investigate the Safety and Immunogenicity of the SF2a-TT15 Synthetic Carbohydrate-based Conjugate Vaccine Against Shigella Flexneri 2aCompletedNCT04602975Phase 2
- A Baseline Study in Support of Clinical Evaluation of an Oral Shigella Vaccine Development in AfricaCompletedNCT04312906
- A Study to Determine If a New Shigella Vaccine is Safe, Induces Immunity and The Best Dose Among Kenyan InfantsCompletedNCT04056117Phase 1/2
- Ciprofloxacin Versus Azithromycin for Children Hospitalised With DysenteryCompletedNCT03854929Phase 4
- Multidrug Resistant Shigella Infection in BangladeshStatus unknownNCT03778125
- Safety Study of S.Flexneriza-S.Sonnei Bivalent Conjugate Vaccine in Healthy Volunteers Aged Above 3 MonthsCompletedNCT03561181Phase 1
- Safety, Immunogenicity and Efficacy Study of Inactivated Whole Cell Shigella Flexneri 2a Vaccine With and Without dmLT in AdultsWithdrawnNCT03038243Phase 2
- SF2a-TT15 Conjugate Vaccine in Healthy Adult VolunteersCompletedNCT02797236Phase 1
- Phase 1 Study of dmLT ID Vaccination in Healthy AdultsCompletedNCT02531685Phase 1
- Safety and Tolerability of a Bioconjugate Vaccine Against Shigella Flexneri 2aCompletedNCT02388009Phase 1
- Diagnosis of Neglected Tropical Diseases Among Patients With Persistent Digestive DisordersCompletedNCT02105714
- Evaluate a New Shigella Sonnei Vaccine Administered Either by Intradermal, Intranasal or Intramuscular Route in Healthy AdultsCompletedNCT02034500Phase 1
- A Registry Study on Xiyanping(a Chinese Medicine Injection) Used in Fifty HospitalsStatus unknownNCT01612572
- Safety and Efficacy Study of CVD 1208S, a Live, Attenuated Oral Vaccine to Prevent Shigella Infection Using cGMPCompletedNCT01531530Phase 1
- Shigella Sonnei OSPC-rDT Conjugate VaccineWithdrawnNCT01399424Phase 1
- Shigella Sonnel O-SPC/rBRU Conjugate VaccineCompletedNCT01369927Phase 1
- Safety and Immunogenicity of Two Live, Attenuated Oral Shigella Sonnei Vaccines: WRSs2 and WRSs3CompletedNCT01336699Phase 1
- Safety and Reactogenicity of Bioconjugate Vaccine to Prevent ShigellaCompletedNCT01069471Phase 1
- Safety and Efficacy Study of CVD 1208S, a Live, Attenuated Oral Vaccine to Prevent Shigella Infection: Phase IIaTerminatedNCT00866476Phase 2
- Safety and Efficacy Challenge Study of CVD 1208S, a Live, Attenuated Oral Vaccine to Prevent Shigella: Phase IIbTerminatedNCT00866242Phase 2
- Therapeutic Induction of Endogenous AntibioticsCompletedNCT00800930Phase 2
- Zinc Supplementation in Shigella PatientsCompletedNCT00321126Phase 3
- Healthy Adult Volunteer Study for Two Doses of a Shigella VaccineCompletedNCT00210288Phase 2
- Invaplex 50 Vaccine Dose-RangingCompletedNCT00082069Phase 1